ReviewRole of Lifestyle and Oral Anti-Diabetic Agents to Prevent Type 2 Diabetes Mellitus and Cardiovascular Disease
Section snippets
Prediabetes and Cardiovascular Risk
Because the average interval between the onset of β-cell dysfunction and the development of overt DM is 10 years,2 there exists a window of opportunity for DM prevention. This interval has been termed “prediabetes” and is defined by an abnormal response to oral glucose tolerance testing, in the form of IGT and/or IFG (Figure 1).3 Epidemiologic evidence suggests that this long period of glucose dysregulation, characterized first by postprandial hyperglycemia alone and progressing to fasting
Lifestyle modification
Epidemiologic studies suggest an association between a favorable lifestyle and improved metabolic parameters. The Insulin Resistance Atherosclerosis Study (IRAS) demonstrated that increasing participation in vigorous and nonvigorous exercise, as assessed by recall of physical activities on a weekly and yearly basis, was correlated with improved insulin sensitivity as measured by an intravenous glucose tolerance test in a group of subjects with normal glucose tolerance, IGT, and early type 2 DM.9
Discussion
Despite the increased risk for cardiovascular morbidity and mortality in patients also at risk for the development of DM, little evidence is available to guide the choice of glycemic therapy for these patients. Although a growing body of evidence indicates that it is possible to improve metabolic parameters (such as hemoglobin A1c and lipid levels) through the use of lifestyle modification or oral antidiabetic agents, and that a delay in DM onset is achievable, the effect of these modifications
Acknowledgment
We wish to acknowledge the NAVIGATOR Trial Executive Committee, Stephen Haffner, MD, Rury Holman, MD, and John McMurray, MD, for their support.
References (34)
- et al.
Cardiovascular therapies and risk for development of diabetes
J Am Coll Cardiol
(2004) - et al.
STOP-NIDDM Trial Research GroupAcarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Lancet
(2002) - et al.
PROactive InvestigatorsSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study: a randomised controlled trial
Lancet
(2005) The PROactive study: some answers, many questions
Lancet
(2005)The metabolic syndrome
Med Clin N Am
(2004)- et al.
Obesity and type 2 diabetes
Endocrinol Metab Clin North Am
(2003) - et al.
Gender and racial differences in lipoprotein subclass distributions: the STRRIDE study
Atherosclerosis
(2004) UK Prospective Diabetes Study 16: overview of 6 years’ therapy of type 2 diabetes
Diabetes
(1995)Standards of medical care for patients with diabetes mellitus
Diabetes Care
(2003)- et al.
The relationship between glucose and incident cardiovascular eventsA metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years
Diabetes Care
(1999)
Glucose: a continuous risk factor for cardiovascular disease
Diabetic Med
Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk)
BMJ
Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?
Diabetes Care
Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria
Lancet
Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance Atherosclerosis Study
JAMA
Effects of the amount and intensity of exercise on plasma lipoproteins
N Engl J Med
Effects of diet and exercise in preventing NIDDM in people with impaired glucose toleranceThe Da Qing IGT and Diabetes Study
Diabetes Care
Cited by (10)
Effect of valsartan on the incidence of diabetes and cardiovascular events
2010, New England Journal of MedicineEffect of apple cider Vinegar on blood glucose level in diabetic mice
2015, Pharmaceutical Sciences
- 1
Drs. Bethel and Califf received grant support from Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.